Presentation highlights Nurix’s innovation and leadership in targeted protein modulation, including ligase inhibition
Unique mechanism of action, an intramolecular glue, locks the E3 ligase Casitas B-lineage lymphoma proto-oncogene B (CBL-B) in a closed inactive state
Phase 1 trial ongoing as monotherapy and in combination with paclitaxel in patients with a range of oncology indications
March 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutic